Rendering

Component: (Network and Table)
Network
100190 - Disclosure - Summary of Significant Accounting Policies (Tables)
(http://www.acadia-pharm.com/20161231/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0001070494 (http://www.sec.gov/CIK)
Accounting Policies [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Accounting Policies [Abstract]
 
Schedule of Estimated Useful Lives by Major Asset Category

Estimated useful lives by major asset category are as follows:

 

 

 

Useful Lives

Machinery and equipment

 

5 to 7 years

Computers and software

 

3 years

Furniture and fixtures

 

10 years

 

  
Assumptions Used to Estimate Fair Value of Employee Stock Options

The estimated fair value of each stock option and purchase right, including the effect of estimated forfeitures, is then expensed over the requisite service period, which is generally the vesting period. The following assumptions were used during these periods:

 

 

Years Ended December 31,

 

 

 

2016

 

 

2015

 

 

2014

 

Stock Options:

 

 

 

 

 

 

 

 

 

 

 

 

Expected volatility

 

 

78

%

 

 

89

%

 

 

93

%

Risk-free interest rate

 

1-2%

 

 

 

1-2

%

 

 

1-2

%

Expected dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

Expected life of options in years

 

 

5.7

 

 

 

5.7

 

 

 

5.7

 

 

  
Assumptions Used to Estimate Fair Value of Employee Stock Purchase Plan Rights

 

 

Years Ended December 31,

 

 

 

2016

 

 

2015

 

 

2014

 

Employee Stock Purchase Plan:

 

 

 

 

 

 

 

 

 

 

 

 

Expected volatility

 

 

60-77

%

 

 

51-59

%

 

 

44-95

%

Risk-free interest rate

 

 

0.4-1.0

%

 

 

0.1-0.9

%

 

 

0.1-0.5

%

Expected dividend yield

 

 

0

%

 

 

0

%

 

 

0

%

Expected life in years

 

0.5-2.0

 

 

0.5-2.0

 

 

0.5-2.0

 

 

  
Summary of Stock-based Compensation Expense Included in Statements of Operations

The table below summarizes the total stock-based compensation expense included in the Company’s statements of operations for the periods presented (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2016

 

 

2015

 

 

2014

 

Cost of product sales

 

$

1,218

 

 

$

—

 

 

$

—

 

Research and development

 

 

18,050

 

 

 

12,171

 

 

 

5,191

 

Sales, general and administrative

 

 

35,997

 

 

 

28,023

 

 

 

10,848

 

 

 

$

55,265

 

 

$

40,194

 

 

$

16,039